Shopping Cart 0
Cart Subtotal
AED 0

Myovant Sciences Ltd (MYOV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Myovant Sciences Ltd (Myovant), a subsidiary of Roivant Sciences Ltd, is a biopharmaceutical company that develops and commercializes new treatments for women's diseases and endocrine disorders. The company's products include relugolix, an oral small molecule that functions as a gonadotropin-releasing hormone receptor antagonist targeting conditions such as heavy menstrual bleeding associated with uterine fibroids and others. It also offers MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation in assisted reproduction. The company has operations in the US, Ireland and Switzerland. Myovant is headquartered in London, the UK.

Myovant Sciences Ltd (MYOV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Myovant Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Private Equity 10

Myovant Sciences Raises USD100 Million in Financing of Shares and Notes 10

Partnerships 12

Myovant Sciences Enters into Agreement with Flo Health 12

Myovant Sciences Enters into Option Agreement with Roivant Sciences 13

Licensing Agreements 14

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 14

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 15

Equity Offering 16

Myovant Sciences Raises USD75 Million in Public Offering of Shares 16

Myovant Sciences Raises USD22.5 Million in Private Placement of Shares 18

Myovant Sciences Plans to Raise up to USD300 Million in Public Offering of shares 19

Myovant Sciences Completes IPO for USD217.5 Million 20

Myovant Sciences Ltd-Key Competitors 22

Myovant Sciences Ltd-Key Employees 23

Myovant Sciences Ltd-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

Aug 07, 2018: Myovant Sciences reports financial results for first fiscal quarter ended June 30, 2018 25

Jun 07, 2018: Myovant Provides Corporate Update and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2018 26

Feb 13, 2018: Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017 28

Nov 13, 2017: Myovant Sciences Provides Corporate Update and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2017 30

Aug 10, 2017: Myovant Sciences Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2017 32

Corporate Communications 34

Jul 19, 2017: Myovant Bolsters Executive Team with Key Management Appointments 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Myovant Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Myovant Sciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Myovant Sciences Raises USD100 Million in Financing of Shares and Notes 10

Myovant Sciences Enters into Agreement with Flo Health 12

Myovant Sciences Enters into Option Agreement with Roivant Sciences 13

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 14

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 15

Myovant Sciences Raises USD75 Million in Public Offering of Shares 16

Myovant Sciences Raises USD22.5 Million in Private Placement of Shares 18

Myovant Sciences Plans to Raise up to USD300 Million in Public Offering of shares 19

Myovant Sciences Completes IPO for USD217.5 Million 20

Myovant Sciences Ltd, Key Competitors 22

Myovant Sciences Ltd, Key Employees 23

Myovant Sciences Ltd, Subsidiaries 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Myovant Sciences Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Myovant Sciences Ltd (Myovant), a subsidiary of Roivant Sciences Ltd, is a biopharmaceutical company that develops and commercializes new treatments for women's diseases and endocrine disorders. The company's products include relugolix, an oral small molecule that functions as a gonadotropin-releasing hormone receptor antagonist targeting conditions such as heavy menstrual bleeding associated with uterine fibroids and others. It also offers MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation in assisted reproduction. The company has operations in the US, Ireland and Switzerland. Myovant is headquartered in London, the UK.

Myovant Sciences Ltd (MYOV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Myovant Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Private Equity 10

Myovant Sciences Raises USD100 Million in Financing of Shares and Notes 10

Partnerships 12

Myovant Sciences Enters into Agreement with Flo Health 12

Myovant Sciences Enters into Option Agreement with Roivant Sciences 13

Licensing Agreements 14

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 14

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 15

Equity Offering 16

Myovant Sciences Raises USD75 Million in Public Offering of Shares 16

Myovant Sciences Raises USD22.5 Million in Private Placement of Shares 18

Myovant Sciences Plans to Raise up to USD300 Million in Public Offering of shares 19

Myovant Sciences Completes IPO for USD217.5 Million 20

Myovant Sciences Ltd-Key Competitors 22

Myovant Sciences Ltd-Key Employees 23

Myovant Sciences Ltd-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

Aug 07, 2018: Myovant Sciences reports financial results for first fiscal quarter ended June 30, 2018 25

Jun 07, 2018: Myovant Provides Corporate Update and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2018 26

Feb 13, 2018: Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017 28

Nov 13, 2017: Myovant Sciences Provides Corporate Update and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2017 30

Aug 10, 2017: Myovant Sciences Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2017 32

Corporate Communications 34

Jul 19, 2017: Myovant Bolsters Executive Team with Key Management Appointments 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Myovant Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Myovant Sciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Myovant Sciences Raises USD100 Million in Financing of Shares and Notes 10

Myovant Sciences Enters into Agreement with Flo Health 12

Myovant Sciences Enters into Option Agreement with Roivant Sciences 13

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 14

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 15

Myovant Sciences Raises USD75 Million in Public Offering of Shares 16

Myovant Sciences Raises USD22.5 Million in Private Placement of Shares 18

Myovant Sciences Plans to Raise up to USD300 Million in Public Offering of shares 19

Myovant Sciences Completes IPO for USD217.5 Million 20

Myovant Sciences Ltd, Key Competitors 22

Myovant Sciences Ltd, Key Employees 23

Myovant Sciences Ltd, Subsidiaries 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Myovant Sciences Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.